Venous thromboembolism (VTE) is a frequent complication of malignancy, and its incidence
has increased markedly in recent years. VTE itself can directly lead to patient mortality, and
is the second leading cause of death in patients with cancer. Furthermore, emerging data
suggest that activation of coagulation in malignancy is integrally linked with tumor biology,
particularly with angiogenesis. The development of the clinical hypercoagulable state is also
linked with adverse prognosis in patients with cancer, including patients receiving systemic …